There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Cefuroxime Axetil should be used during pregnancy only if clearly needed.
Nursing Mothers Because cefuroxime is excreted in human milk, caution should be exercised when Cefuroxime Axetil is administered to a nursing woman. Pediatric Use The safety and effectiveness of Cefuroxime Axetil have been established for pediatric patients aged 3 months to 12 years for acute bacterial maxillary sinusitis based upon its approval in adults.
Use of Cefuroxime Axetil in pediatric patients is supported by pharmacokinetic and safety data in adults and pediatric patients, and by clinical and microbiological data from adequate and well-controlled trials of the treatment of acute bacterial maxillary sinusitis in adults and of acute otitis media with effusion in pediatric patients.
It is also supported by postmarketing adverse events surveillance. No overall differences in safety or effectiveness were observed between these subjects and younger adult subjects. Reported clinical experience has not identified differences in responses between the elderly and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.
Cefuroxime is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Overdosage Overdosage of cephalosporins can cause cerebral irritation leading to convulsions or encephalopathy. Serum levels of cefuroxime can be reduced by hemodialysis and peritoneal dialysis.
Cefuroxime Axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration. CDAD must be considered in all patients who present with diarrhea following antibiotic use.
Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.
Potential For Microbial Overgrowth The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. Development Of Drug-Resistant Bacteria Prescribing CEFTIN either in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertility Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime axetil in a battery of bacterial mutation tests.
Positive results were obtained in an in vitro chromosome aberration assay; however, negative results were found in an in vivo micronucleus test at doses up to 1. There are no adequate and well-controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response, CEFTIN should be used during pregnancy only if clearly needed.
Pediatric Use The safety and effectiveness of CEFTIN have been established for pediatric patients aged 3 months to 12 years for acute bacterial maxillary sinusitis based upon its approval in adults.
Use of CEFTIN in pediatric patients is supported by pharmacokinetic and safety data in adults and pediatric patients, and by clinical and microbiological data from adequate and well-controlled trials of the treatment of acute bacterial maxillary sinusitis in adults and of acute otitis media with effusion in pediatric patients.
It is also supported by postmarketing adverse events surveillance. No overall differences in safety or effectiveness were observed between these subjects and younger adult subjects.
The presence of cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method. Because animal reproduction studies are not always predictive of human response, Cefuroxime Axetil should be used 500mg pregnancy only if clearly needed. Probenecid Concomitant tablet cefuroxime probenecid with Cefuroxime Axetil tablets increases serum concentrations of cefuroxime [see Clinical Pharmacology Counsel patients to consider alternate supplementary non-hormonal contraceptive measures during treatment. Pharmacokinetics Absorption After oral administration, Cefuroxime Axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific 500mg in the intestinal mucosa and blood to cefuroxime. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, cefuroxime tablet 500mg, and it may be useful to monitor renal function. Overdosage Overdosage of cephalosporins can cause cerebral irritation leading to convulsions or encephalopathy. Cefuroxime must be considered in all patients who present tablet diarrhea following antibiotic use. Histamine-2 H2 antagonists and proton pump inhibitors should be avoided.
© Copyright 2017 Cefuroxime tablet 500mg *** Find patient medical information for Cefuroxime Axetil Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings..